Genzyme Renagel Inventory Stable By 2003; Wholesaler Agreements Planned
Executive Summary
Genzyme will use formal agreements with wholesalers to draw down excess Renagel inventory levels by the beginning of 2003, Renagel General Manager John Butler said during a conference call to announce revised earnings estimates Sept. 16
You may also be interested in...
Genzyme Renagel Growth To Come From Medicare Rx, Kidney Disease Use
Genzyme expects results from a Phase IV Renagel outcomes study to bolster the phosphate binder's long-term growth prospects, Renal Division General Manager John Butler told investors Feb. 19
Genzyme Renagel Growth To Come From Medicare Rx, Kidney Disease Use
Genzyme expects results from a Phase IV Renagel outcomes study to bolster the phosphate binder's long-term growth prospects, Renal Division General Manager John Butler told investors Feb. 19
Genzyme Renagel Margin Improves As Private Contracts Grow
Genzyme is seeing increased profitability in Renagel sales due to a more favorable reimbursement mix